Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry

Valeria Aiello1,4, Michele Fusaroli2,4, Emanuel Raschi2, Massimiliano Palazzini3, Lilio Hu1, Simona Barbuto1, Elisabetta Poluzzi2 and Irene Capelli1

1Nephrology, Dialysis and Renal Transplant Unit, IRCCS - Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2Pharmacology Unit, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy; and 3Cardiology Unit, Department of Experimental Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Correspondence: Irene Capelli, Nephrology, Dialysis and Renal Transplant Unit, IRCCS - Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy E-mail: irenecapelli4@unibo.it

4VA and MF contributed equally as first authors.

Received 3 May 2021; revised 16 June 2021; accepted 22 June 2021; published online 15 July 2021

Kidney Int Rep (2021) 6, 2472–2477; https://doi.org/10.1016/j.ekir.2021.06.028
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

KEYWORDS: ADPKD; FAERS registry; pharmacovigilance; thromboembolism; tolvaptan

BACKGROUND

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder (estimated prevalence of 1 per 1000–1 per 2500 live births)1 characterized by the development and growth of multiple bilateral cysts eventually leading to end-stage renal disease and renal replacement therapy.1

Tolvaptan, a selective vasopressin V2 receptor antagonist, is currently the only pharmacologic agent approved for ADPKD capable of slowing the kidney cyst growth and the progression of kidney disease.2 The resulting aquaretic adverse events (AEs) (polyuria, pollakiuria, and nocturia) may cause dehydration and did not seem to diminish over time,2 thus supporting the need to inform patients for adequate liquid intake and maintaining long-term vigilance.

Data on the risk/benefit profile of tolvaptan in ADPKD come mainly from randomized controlled trials and small real-world studies.3 The latest prospective, multinational, open-label safety study enrolling subjects who completed previous trials (median exposure 651 days) confirmed the occurrence of treatment-emergent aquaretic AEs and the importance of tight hepatic monitoring as effective risk minimization strategy.4

Therefore, postmarketing studies are needed to evaluate rare and unexpected AEs, which are not fully appreciated in randomized controlled trials.5

We herein describe the occurrence of acute pulmonary thromboembolism in a patient with risk factors exposed to tolvaptan. To evaluate the possible association between tolvaptan and thromboembolism, we also analyzed the Food and Drug Administration Adverse Event Reporting System.

CASE PRESENTATION

A 44-year-old woman presented to the emergency department with persistent dyspnea and chest pain on July 2020. She referred a past medical history of portal vein and caudal vena cava thrombosis during estrogen-progestogen therapy in 2009, treated with warfarin for 11 months. A heterozygous mutation for factor V Leiden was found. The patient was also affected by ADPKD and started administration of tolvaptan 60 mg/daily in October 2019 (120 mg/daily at hospital admission).

On physical examination, tachycardia of 139 beats per minute and increased respiratory rate of 30/min
with slight reduction of oxygen saturation level (96%) were observed, without signs of heart failure. Burning pain on lower limbs, without clinical signs of deep vein thrombosis, was referred. Kidney function was stable (creatinine 1.09 mg/dl, estimated glomerular filtration rate 62 ml/min) with signs of fibrinolysis as D-dimer was 2.97 mg/l (normal value <0.55 mg/l). Troponin I was 12.8 ng/l with normal B-type natriuretic peptide (30 pg/ml).

In the suspicion of acute pulmonary embolism, a contrast-enhanced computed tomography angiogram was performed and confirmed the presence of bilateral massive pulmonary thromboembolism. Inferior vena cava compression by hepatic or right renal cysts was ruled out by computed tomography and magnetic resonance imaging. Results of echocardiography performed revealed mild dilation and hypokinesia of the right ventricle with positive McConnell’s sign (hypokinetik right ventricular free wall with sparing of the apex); the inferior vena cava was completely collapsed. Troponin I was 12.8 ng/l (the 99th percentile upper reference limit was 11.6 ng/l). The patient was deemed at intermediate high-risk pulmonary embolism, so anticoagulation treatment with low-molecular-weight heparin (enoxaparin 8000 U twice daily) was started plus i.v. fluid loading. Her kidney function was stable (creatinine = 0.86 mg/dl), with slightly elevated liver function enzymes (aspartate transaminase = 42 U/l, alanine transaminase = 78 U/l, gamma-glutamyl transferase = 66 U/l). Tolvaptan was discontinued, and enoxaparin was switched to a direct oral anticoagulant, rivaroxaban 20 mg.

She was discharged on day 17 with stable medical condition (creatinine = 0.8 mg/dl, aspartate transaminase/alanine transaminase/gamma-glutamyl transferase = 40/82/55 U/l), without resuming tolvaptan. After 3 months of anticoagulation therapy, reduction of the thrombus at the main pulmonary trunk and partial occlusion at the left pulmonary artery with left lung infarct lesions was found; some segmental filling defects were also revealed in the right pulmonary basilar branches. At the cardiologic assessment at 6 months, the patient was still asymptomatic and despite echocardiogram results revealed a normal right ventricle size and contractile function with normal pulmonary artery pressure (15 + 5 mm Hg), the complete workup for chronic thromboembolic pulmonary hypertension was completed according with both guidelines of the European Society of Cardiology on acute pulmonary embolism and pulmonary hypertension. Finally, chronic thromboembolic disease (persistence of thromboembolic burden but without pulmonary hypertension at rest) was confirmed and the patient received lifelong anticoagulation therapy for 2 previous venous thromboembolism episodes not related to major transient or reversible risk factors. Kidney and liver function enzymes were in normal range (creatinine = 0.93 mg/dl, aspartate transaminase = 15 U/l, alanine transaminase = 23 U/l, gamma-glutamyl transferase = 23 U/l).

Food and Drug Administration Adverse Event Reporting System Analysis
The Food and Drug Administration Adverse Event Reporting System is a publicly available global spontaneous reporting system collecting real-world data on suspected adverse drug reactions. We retained reports of interest, specifically “embolic and thrombotic events,” up to September 2020, building on previous experience in pharmacovigilance. The cases were described in terms of demographic and clinical information, including causality assessment (see Supplementary Methods).

Overall, 57 thromboembolic events were found (24 explicitly venous and 21 arterial), involving mostly the lung (in 32% of the cases), periphery (23%), nervous system (21%), and heart (18%), with pulmonary embolism being the most frequently reported AE (13 cases).

There were 32 cases (61.5% of the reports specifying sex) that occurred in males, 61.4% were submitted by physicians, and the median age was 51 years. It should be noted that 12 cases concerned people of more than 60 years of age, but this is in line with the lack of age limits for reimbursement in multiple countries (6 of these reports are from Japan and 2 from France). Most of the reports were serious (65%), such as resulting in death (6 cases), life-threatening event, disability, hospitalization, requiring intervention, or another serious event. Median latency (i.e., time from the prescription of tolvaptan and the onset of AE), calculated on 19 cases, was approximately 5 months, with 50% of the thromboembolic events occurring between 2 months and 10 months. In 34 cases (59.6%) tolvaptan was discontinued (positive dechallenge result in 17 cases).

Cardiovascular drugs, mainly amlodipine, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, were recorded in 35 cases, and antigout agents were found in 15 cases. Potential risk factors were recorded in 16 cases (28%), mostly sex hormones and diuretics (11% each). In 11 cases (19.3%), antithrombotic therapy was documented (in 3 cases specified as therapy for the thromboembolic event). Most frequently co-reported events were thirst and pollakiuria (6 cases each). A highly probable/
| Case  | Thromboembolic event                      | Country | Age | Sex | Latency (d) | Discontinuation | Risk factors                  | Antithrombotics | Aquaretic events | Seriousness | Causality       |
|-------|------------------------------------------|---------|-----|-----|-------------|-----------------|-----------------------------|----------------|----------------|-------------|-----------------|
| 1     | Venous thromboembolism                   |         |     |     |             |                 |                             |                |                |             |                 |
| 2     | Deep vein thrombosis; pulmonary embolism | US      | 51  | M   | 54          | N               | Citalopram                | HO             |                |             | Possible        |
| 3     | Pulmonary embolism; thrombosis           | DE      | F   | Y   | 1035        | Y (D)           | Enoxaparin                 | HO             |                |             | Highly probable |
| 4     | Deep vein thrombosis; pulmonary embolism | US      | 46  | M   |             |                 |                             |                |                |             |                 |
| 5     | Venous thromboembolism                   | DE      | 46  | M   |             | N               | Desogestrel               | HO             |                |             |                 |
| 6     | Venous thromboembolism                   | GB      | 48  | F   |             | N               | Enoxaparin                 | HO             |                |             |                 |
| 7     | Venous thromboembolism                   | FR      | 67  | M   | 1           | Y (D)           | Escitalopram; furosemide; ASA | HO             |                |             |                 |
| 8     | Venous thromboembolism                   | FR      | 67  | M   | 69          | Y (D)           | Enoxaparin                 | HO             |                |             |                 |
| 9     | Venous thromboembolism                   | US      | 42  | M   |             | Y               | Enoxaparin                 | HO             |                |             |                 |
| 10    | Venous thromboembolism                   | DE      | 51  | F   |             | N               | Spironolactone; torasemide | HO             |                |             |                 |
| 11    | Venous thromboembolism                   | CA      | 33  | F   |             | Y (D)           | Medroxyprogesterone        | HO             |                |             |                 |
| 12    | Venous thromboembolism                   | US      | 51  | M   |             | N               | Pollakiuria                | HO             |                |             |                 |
| 13    | Venous thromboembolism                   | US      | 58  | F   |             | N               | DEA                        | HO             |                |             |                 |
| 14    | Venous thromboembolism                   | ES      | M   | N   |             | N               | DEA                        | HO             |                |             |                 |
| 15    | Venous thromboembolism                   | US      | 35  | M   |             | Y               | Thirst                     | LT             |                |             |                 |
| 16    | Venous thromboembolism                   | US      | 35  | M   |             | N               | Erythropoietin              | DEA            |                |             |                 |
| 17    | Venous thromboembolism                   | AU      | F   | N   |             |                 | Nocturia                   | HO             |                |             |                 |
| 18    | Venous thromboembolism                   | US      | M   | N   |             |                 | Testosterone               | HO             |                |             |                 |
| 19    | Venous thromboembolism                   | US      | 77  | M   | 101         | N               | Testosterone               | DEA            |                |             |                 |
| 20    | Venous thromboembolism                   | AU      | F   | N   |             |                 | DEA                        | HO             |                |             |                 |
| 21    | Venous thromboembolism                   | JP      | 58  | M   | 144         | Y (D)           | Hypernatremia, dehydration | HO             |                |             | Highly probable |
| 22    | Venous thromboembolism                   | JP      | 43  | M   |             |                 | Warfarin                   | HO             |                |             |                 |
| 23    | Venous thromboembolism                   | FR      | 40  | F   |             |                 | Probable                   |                |                |             |                 |
| 24    | Venous thromboembolism                   | DE      | F   | N   |             |                 | Probable                   |                |                |             |                 |

(Continued on following page)
### Table 1. (Continued) Individual case assessment

| Case | Thromboembolic event | Country | Age | Sex | Latency (d) | Discontinuation | Risk factors | Antithrombotics | Aquaretic events | Seriousness | Causality |
|------|-----------------------|---------|-----|-----|------------|----------------|--------------|--------------|----------------|-------------|-----------|
| 1    | Hepatic artery thrombosis | BE      | 45  | F   | 201        | Y              | Nomegestrol  |              |               |             | Possible  |
| 2    | Retinal artery occlusion | JP      | 75  | M   | Y (D)      |                |              |              |               |             | HO        |
| 3    | Myocardial infarction   | DE      | 51  |     |            | Y              |              |              |               |             | Probable  |
| 4    | Cerebellar infarction; stress cardiomyopathy | JP | 66  | F   | 271        | Y (D)          |              |              |               |             | HO        |
| 5    | Myocardial infarction   | FR      | 57  | M   | 184        | Y (D)          |              |              |               |             | HO        |
| 6    | Amaurosis               | DE      | 54  | F   | 298        | Y (D)          | ASA          |              |               |             | HO        |
| 7    | Transient ischemic attack | JP    | 62  | F   | 315        | Y (D)          |              |              |               |             | HO        |
| 8    | Lacunar infarction      | JP      | 57  | M   |            | Y              | Furosemide   | Hypernatremia |             |             | Possible  |
| 9    | Transient ischemic attack | JP    | 50  | F   |            | Y (D)          |              |              |               |             | Highly prob |
| 10   | Myocardial infarction   | IT      | 40  | M   |            | Y (D)          |              |              |               |             | HO        |
| 11   | Myocardial infarction   | CA      | 49  | M   |            | N              | Warfarin     | DEA          | Probable       |             | Probable  |
| 12   | Blindness transient     | CA      | 55  | F   | 1          | N              | Hydrochlorothiazide | Pollakiuria; hypotension |     | Possible  |
| 13   | Acute myocardial infarction | SE    | 44  | F   |            | N              |              |              |               |             | HO        |
| 14   | Myocardial infarction   | US      | 65  | M   | 155        | Y              |              |              |               |             | Probable  |
| 15   | Retinal vein occlusion  | FR      | 44  |     |            | N              |              |              |               |             | Probable  |
| 16   | Myocardial infarction   | CA      | 49  | M   |            | N              | Warfarin     | DEA          | Probable       |             | Probable  |
| 17   | Amaurosis fugax         | AT      | 61  | F   |            | N              | Hydrochlorothiazide |              |               |             | HO        |
| 18   | Peripheral artery occlusion | AU    | 47  | M   |            | N              | Pollakiuria  |              |               |             | Probable  |
| 19   | Stress cardiomyopathy   | IT      | 45  | F   |            | Y (D)          |              |              |               |             | HO        |
| 20   | Acute myocardial infarction | KR    | 36  | M   |            | N              |              | DEA          | Probable       |             | Probable  |
| 21   | Transient ischemic attack | US    | 66  | M   |            | Y (D)          | Fluticasone  | Clopidogrel   | Thirst; hypotension; hypernatremia; dehydration; acute kidney injury | HO | Possible  |

**Other nonspecified thromboembolism**

| Case | Thromboembolic event | Country | Age | Sex | Latency (d) | Discontinuation | Risk factors | Antithrombotics | Aquaretic events | Seriousness | Causality |
|------|-----------------------|---------|-----|-----|------------|----------------|--------------|--------------|----------------|-------------|-----------|
| 1    | Cerebral infarction   | JP      | 59  | M   |            | Y              |              |              |               |             | Probable  |
| 2    | Disseminated intravascular coagulation | JP | 51  | F   | 148        | Y              |              |              |               |             | DEA        |

**Other nonspecified thromboembolism**

| Case | Thromboembolic event | Country | Age | Sex | Latency (d) | Discontinuation | Risk factors | Antithrombotics | Aquaretic events | Seriousness | Causality |
|------|-----------------------|---------|-----|-----|------------|----------------|--------------|--------------|----------------|-------------|-----------|
| 3    | Thrombosis            | US      | 40  | F   |            | Y              | Escitalopram | Apixaban     | Thirst; pollakiuria |             |            |
| 4    | Cerebral infarction   | JP      | 58  | F   |            | Y              |              | clopidogrel  |               |             | Probable  |

(Continued on following page)
probable causality was found in 51% of the cases and probable in 49% (Table 1).

**DISCUSSION AND CONCLUSION**

After the publication of TEMPO 3:4 trial, tolvaptan was approved worldwide to slow the progression of cyst development and end-stage renal disease of ADPKD in adults. Aquaretic events and liver injury were key treatment-emergent AEs, whereas thromboembolism was not identified as a safety issue.

To our knowledge, this is the first comprehensive real-world characterization of thromboembolic events to tolvaptan in patients with ADPKD collected from a real-world global spontaneous reporting system. Only 1 case report was published, in which venous thromboembolism occurred in a 60-year-old man after 6 days of persistent watery diarrhea, a likely cause of prothrombotic dehydration.8

It should be noted that chronic kidney disease is a well-established risk factor for venous thromboembolism. Notably, for chronic kidney disease and end-stage renal disease, this increased risk is due to increased tissue factor and fibrinogen levels, enhanced activation of factors XIIa and VIIa, and reduced tissue plasminogen activator 4.7–9 Furthermore, many known conditions in patients with ADPKD may add up and raise the risk of thrombosis, such as erythrocytosis,52 inferior vena cava compression,53–56 and hepatic venous outflow obstruction with or without Budd-Chiari syndrome.57–59 Therefore, it could be stated that tolvaptan may have a contributory rather than a causative role in thromboembolism, although the association is quite unclear. More studies on the matter are required to better understand thromboembolic risk in these patients and help stratify them to identify those who could be more at risk of developing this life-threatening condition.

The following 2 clues emerged from our data: (i) concomitant aquaretic events (including the use of diuretics) and drug-related risk factors (especially sex hormones) were recorded in a nonnegligible proportion of thromboembolic events and (ii) even in the presence of increased patient susceptibility (i.e., Leiden V factor mutation and previous thromboembolism during estrogen-progestogen therapy), the onset was delayed up to 9 to 10 months. Regarding arterial and non-specified thromboembolic events, the highest ratio of patients older than 60 years (29% and 25%, respectively, vs. 13% in venous events) may suggest a possible confounding or contributory role of age for nonvenous cases.

Taken together, these data (i) strengthen the importance of routine medication review to minimize

**Table 1. (Continued) Individual case assessment**

| Case | Thromboembolic event | Country | Age | Sex | Latency (d) | Discontinuation | Risk factors | Antithrombotics | Aquaretic events | Seriousness | Causality |
|------|----------------------|---------|-----|-----|-------------|-----------------|--------------|----------------|----------------|-------------|-----------|
| 5    | Cerebral infarction  | JP      | 66  | M   | Y           | DS              | Probable     |                |                |             |           |
| 6    | Thrombosis           | US      | 56  | M   | 1           | N               | Probable     |                |                |             |           |
| 7    | Cerebral infarction  | JP      | 80  | M   | HO          |                 | Probable     |                |                |             |           |
| 8    | Thrombosis           | CA      | 49  | M   | Polydipsia; nocturia | Probable     |                |                |                |             |           |
| 9    | Thrombosis           | US      | 32  | M   | N            | N               | Probable     |                |                |             |           |
| 10   | Cerebral infarction  | JP      | 63  | M   | Furosemide  | HO              | Probable     |                |                |             |           |
| 11   | Cerebral infarction  | TW      | 41  | F   | Y (LD)      |                 | Probable     |                |                |             |           |
| 12   | Cerebrovascular accident | TW | 441 | N |             |                 |              |                |                |             |           |

ASA, acetylsalicylic acid; AT, Austria; AU, Australia; BE, Belgium; CA, Canada; DE, Germany; DS, death; ES, Spain; F, female; FR, France; GB, United Kingdom; HO, hospitalization; ISO, International Organization for Standardization; IT, Italy; JP, Japan; KR, South Korea; LT, life-threatening; M, male; N, no; NL, Netherlands; SE, Sweden; TW, Taiwan; US, United States; Y, yes.

*Countries are coded using their ISO 3166-1 alpha-2 code.*
potential toxic synergism; (ii) support long-term monitoring by nephrologists to timely diagnose signs and typical symptoms, such as edema, sudden leg swelling, thrombophlebitis, shortness of breath, hypoxia, chest pain, polypnea, and tachycardia; and (iii) call for constant epidemiologic surveillance and clarification by means of dedicated registries. Whether formal thrombophilic assessment should be performed when prescribing tolvaptan, particularly in subjects with previous events or other risk factors (including concomitant drugs), remains an unresolved question; further studies of the prevalence of hypercoagulable states in patients with ADPKD are needed.

We acknowledge the limitations of our study, which do not allow to provide incidence rates. Moreover, clinical features (genetics body mass index, patient’s history, comorbidities, inferior vena cava syndrome, infections) and instrumental assessment (ultrasonography and laboratory parameters) to support diagnosis and risk stratification/prediction cannot be fully analyzed. Therefore, causal association cannot be firmly inferred.

In conclusion, although tolvaptan could be effective in retarding the progression of ADPKD, a signal of thromboembolism emerged from the Food and Drug Administration Adverse Event Reporting System. Nephrologists should monitor the occurrence of thromboembolic events for timely assessment and prompt management, including medication review and tolvaptan discontinuation.

**DISCLOSURE**

All the authors declared no competing interests.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

Supplemental References.

Supplementary Methods.

**REFERENCES**

1. co-chairs EAF, Harris T, Sandford R, members EAF. Roundtable participants. European ADPKD forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD forum and multispecialist roundtable participants. *Nephrol Dial Transplant*. 2018;33:563–573. https://doi.org/10.1093/ndt/gfx327.

2. van Gastel MDA, Torres VE. Polycystic kidney disease and the vasopressin pathway. *Ann Nutr Metab*. 2017;70(suppl 1):43–50. https://doi.org/10.1159/000463063.

3. Blair HA. Tolvaptan: a review in autosomal dominant polycystic kidney disease. *Drugs*. 2019;79:303–313. https://doi.org/10.1007/s40265-019-1056-1.

4. Torres VE, Chapman AB, Devuyst O, et al. Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease. *Clin J Am Soc Nephrol*. 2020;16:48–58. https://doi.org/10.2215/CJN.10250620.

5. Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. *Target Oncol*. 2020;15:449–466. https://doi.org/10.1007/s11523-020-00738-6.

6. Konstantinides SV, Meyer G, Becattini C, et al. ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41:543–603. https://doi.org/10.1093/eurheartj/ehz405.

7. Raschi E, Fusaroli M, Ardizzoni A, et al. Thromboembolic events with cyclin-dependent kinase 4/6 inhibitors in the FDA Adverse Event Reporting System. *Cancers*. 2021;13:1758. https://doi.org/10.3390/cancers13081758.

8. Morimoto K, Akai Y, Matsui M, et al. Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease. *CEN Case Rep*. 2017;6:61–65. https://doi.org/10.1007/s13730-016-0245-y.

9. Wattanakit K, Cushman M, Stehman-Breen C, et al. Folsom chronic kidney disease increases risk for venous thromboembolism. *J Am Soc Nephrol*. 2008;19:135–140. https://doi.org/10.1681/ASN.2007030308.

**Table S1.** Adapted World Health Organization-Uppsala Monitoring Centre causality categories.